INCB 3284 is a potent and selective CCR2 receptor antagonist investigated for its therapeutic potential in medical research. It modulates inflammatory and immune pathways by inhibiting CCR2, which reduces the recruitment of monocytes and macrophages to sites of inflammation or tumors. Primarily studied in oncology, it targets biological pathways implicated in cancer progression, including tumor growth and metastasis, by disrupting the tumor microenvironment. Researchers explore its efficacy in inhibiting CCR2-mediated processes and its use in combination therapies to enhance existing cancer treatments. Additionally, INCB 3284 shows promise in treating inflammatory and autoimmune diseases such as rheumatoid arthritis, psoriasis, and atherosclerosis by limiting leukocyte migration. Preclinical studies evaluate its mechanism of action, efficacy, and safety profile to support future clinical trials.